Activated protein C resistance (FV(Leiden)) and thrombosis: factor V mutations causing hypercoagulable states (Q35081838)

6 August 2017

1 reference

title

Activated protein C resistance (FV(Leiden)) and thrombosis: factor V mutations causing hypercoagulable states (English)

1 reference

activated protein C resistance

6 August 2017

1 reference

1 reference

1 reference

Gerry A F Nicolaes

1

1 reference

6 August 2017

Björn Dahlbäck

series ordinal

2

1 reference

6 August 2017

publication date

1 February 2003

1 reference

Hematology / Oncology Clinics of North America

6 August 2017

published in

1 reference

6 August 2017

volume

17

1 reference

6 August 2017

issue

1

1 reference

6 August 2017

page(s)

37-61, vi

1 reference

The coagulation cascade: initiation, maintenance, and regulation

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900097-7

7 January 2021

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900097-7

1 reference

7 January 2021

Activated protein C resistance and thrombosis: molecular mechanisms of hypercoagulable state due to FVR506Q mutation

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900097-7

7 January 2021

Venous thrombosis: a multicausal disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900097-7

7 January 2021

A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900097-7

7 January 2021

A prospective study of the incidence of deep-vein thrombosis within a defined urban population

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900097-7

7 January 2021

The protein C anticoagulant system: inherited defects as basis for venous thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900097-7

7 January 2021

Genetic aspects of venous thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900097-7

7 January 2021

Blood-borne tissue factor: another view of thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900097-7

7 January 2021

Activation of human factor V by factor Xa and thrombin

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900097-7

7 January 2021

Slow activation of factor VIII by thrombin and other enzymes at low temperature

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900097-7

7 January 2021

Thrombin activation of factor VIII: the effect of inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900097-7

7 January 2021

Preparation and properties of bovine factor VIII (antihemophilic factor).

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900097-7

7 January 2021

Enhancement of rabbit jugular vein thrombolysis by neutralization of factor XI. In vivo evidence for a role of factor XI as an anti-fibrinolytic factor

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900097-7

7 January 2021

Thrombin signalling and protease-activated receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900097-7

7 January 2021

Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900097-7

7 January 2021

An update on clinical and basic aspects of the protein C anticoagulant pathway

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900097-7

7 January 2021

Structural basis for the anticoagulant activity of the thrombin-thrombomodulin complex

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900097-7

7 January 2021

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900097-7

1 reference

7 January 2021

High molecular weight complex in human plasma between vitamin K-dependent protein S and complement component C4b-binding protein

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900097-7

7 January 2021

Amino acid residues in thrombin-sensitive region and first epidermal growth factor domain of vitamin K-dependent protein S determining specificity of the activated protein C cofactor function

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900097-7

7 January 2021

The SHBG-like region of protein S is crucial for factor V-dependent APC-cofactor function.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900097-7

7 January 2021

Peptide bond cleavages and loss of functional activity during inactivation of factor Va and factor VaR506Q by activated protein C.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900097-7

7 January 2021

Effects of protein S and factor Xa on peptide bond cleavages during inactivation of factor Va and factor VaR506Q by activated protein C

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900097-7

7 January 2021

Biosynthesis of coagulation Factor V by a human hepatocellular carcinoma cell line.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900097-7

7 January 2021

Characterization of the human factor VIII gene.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900097-7

7 January 2021

Complete cDNA and derived amino acid sequence of human factor V

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900097-7

7 January 2021

Coagulation factors V and VIII and ceruloplasmin constitute a family of structurally related proteins

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900097-7

7 January 2021

Structural investigation of the A domains of human blood coagulation factor V by molecular modeling

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900097-7

7 January 2021

Homology models of the C domains of blood coagulation factors V and VIII: a proposed membrane binding mode for FV and FVIII C2 domains

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900097-7

7 January 2021

Crystal structures of the membrane-binding C2 domain of human coagulation factor V

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900097-7

7 January 2021

Structure of the C2 domain of human factor VIII at 1.5 A resolution

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900097-7

7 January 2021

Electron crystallography of human blood coagulation factor VIII bound to phospholipid monolayers

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900097-7

7 January 2021

Partial glycosylation at asparagine-2181 of the second C-type domain of human factor V modulates assembly of the prothrombinase complex.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900097-7

7 January 2021

Partial glycosylation of Asn2181 in human factor V as a cause of molecular and functional heterogeneity. Modulation of glycosylation efficiency by mutagenesis of the consensus sequence for N-linked glycosylation

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900097-7

7 January 2021

Human factor Va1 and factor Va2: properties in the procoagulant and anticoagulant pathways

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900097-7

7 January 2021

Inherited resistance to activated protein C is corrected by anticoagulant cofactor activity found to be a property of factor V.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900097-7

7 January 2021

The C-terminal region of the factor V B-domain is crucial for the anticoagulant activity of factor V.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900097-7

7 January 2021

Procoagulant and anticoagulant properties of coagulation factor V: factor V Leiden (APC resistance) causes hypercoagulability by dual mechanisms

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900097-7

7 January 2021

Protein C and S deficiency

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900097-7

7 January 2021

Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900097-7

7 January 2021

Resistance to activated protein C as a basis for venous thrombosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900097-7

7 January 2021

Modified test for activated protein C resistance.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900097-7

7 January 2021

Evaluation of a modified APTT-based method for determination of APC resistance in plasma from patients on heparin or oral anticoagulant therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900097-7

7 January 2021

Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900097-7

7 January 2021

Linkage between inherited resistance to activated protein C and factor V gene mutation in venous thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900097-7

7 January 2021

Mutation in blood coagulation factor V associated with resistance to activated protein C.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900097-7

7 January 2021

Activated protein C resistance caused by Arg506Gln mutation in factor Va

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900097-7

7 January 2021

Association of idiopathic venous thromboembolism with single point-mutation at Arg506 of factor V

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900097-7

7 January 2021

World distribution of factor V Leiden

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900097-7

7 January 2021

Mutant factor V (Arg506Gln) in healthy centenarians

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900097-7

7 January 2021

Effect of activated protein C on thrombin generation and on the thrombin potential in plasma of normal and APC-resistant individuals

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900097-7

7 January 2021

Activated protein C resistance, factor V Leiden, and retinal vessel occlusion

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900097-7

7 January 2021

Study of the prothrombin gene 20201 GA variant in FV:Q506 carriers in relationship to the presence or absence of juvenile venous thromboembolism

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900097-7

7 January 2021

Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900097-7

7 January 2021

Functional characterization of recombinant FV Hong Kong and FV Cambridge.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900097-7

7 January 2021

Method-dependent influence of certain polymorphisms in the factor V B-domain on the response to activated protein C

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900097-7

7 January 2021

Recurrent thrombosis due to compound heterozygosity for factor V Leiden and factor V deficiency

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900097-7

7 January 2021

Phenotypic homozygous activated protein C resistance associated with compound heterozygosity for Arg506Gln (factor V Leiden) and His1299Arg substitutions in factor V.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900097-7

7 January 2021

Pseudo-homozygous activated protein C resistance due to coinheritance of heterozygous factor V Leiden mutation and type I factor V deficiency. Variable expression when analyzed by different activated protein C resistance functional assays.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900097-7

7 January 2021

Clinical and laboratory manifestations of anti-factor V antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900097-7

7 January 2021

Development of resistance to activated protein C during pregnancy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900097-7

7 January 2021

Resistance to activated protein C in healthy women taking oral contraceptives.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900097-7

7 January 2021

Risk of venous thromboembolism in users of hormone replacement therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900097-7

7 January 2021

A new variant of interaction between phospholipid antibodies and the protein C system.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900097-7

7 January 2021

The influence of factor VIII on measurement of activated protein C resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900097-7

7 January 2021

Resistance to activated protein C, the FV:Q506 allele, and venous thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900097-7

7 January 2021

Effects of oral contraceptives on hemostasis and thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900097-7

7 January 2021

Decreased plasma tissue factor pathway inhibitor in women taking combined oral contraceptives

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900097-7

7 January 2021

Prospective randomized study of effects of unopposed estrogen replacement therapy on markers of coagulation and inflammation in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900097-7

7 January 2021

Activated protein C resistance in ischemic stroke not due to factor V arginine506-->glutamine mutation.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900097-7

7 January 2021

Reduced response to activated protein C is associated with increased risk for cerebrovascular disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900097-7

7 January 2021

Clinical significance of activated protein C resistance as a potential marker for hypercoagulable state

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900097-7

7 January 2021

Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900097-7

7 January 2021

Acquired APC resistance and oral contraceptives: differences between two functional tests

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900097-7

7 January 2021

Use of the direct RNA amplification technique NASBA to detect factor V Leiden, a point mutation associated with APC resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900097-7

7 January 2021

Evaluation of a tissue factor dependent factor V assay to detect factor V Leiden: demonstration of high sensitivity and specificity for a generally applicable assay for activated protein C resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900097-7

7 January 2021

Sensitivity of the ProC global assay for protein C pathway abnormalities. clinical experience in 899 unselected patients with venous thromboembolism

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900097-7

7 January 2021

A study of Protein S antigen levels in 3788 healthy volunteers: influence of age, sex and hormone use, and estimate for prevalence of deficiency state

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900097-7

7 January 2021

Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900097-7

7 January 2021

10.1016/S0889-8588(02)00097-7

Identifiers

DOI

1 reference

6 August 2017

1 reference